The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO Italy 2020 | Evolving treatment landscape of DLBCL
Gerardo Musuraca, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the changing treatment landscape of diffuse large B-cell lymphoma (DLBCL), and how this is guided by a greater molecular understanding of disease biology and pathogenesis. Dr Musuraca also highlights biological agents that have been developed for the different molecular subtypes of DLBCL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
